Eledon Pharmaceuticals
ELDN
85 hedge funds and large institutions have $111M invested in Eledon Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 26 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 15
4% more ownership
Funds ownership: 64.21% → 68.21% (+4%)
2% more funds holding
Funds holding: 83 → 85 (+2)
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less capital invested
Capital invested by funds: $130M → $111M (-$19.7M)
40% less call options, than puts
Call options by funds: $134K | Put options by funds: $223K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.81M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.15M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.1M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$970K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.92M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.7M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
-$1.47M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.04M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$961K |
ELDN Hedge Fund Activity: Q2 2025 in Review
85 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2025, worth a combined $111M — down 15% from $130M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ELDN positions and 26 closed out — a net gain of 2 holders — while 21 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $7.81M. The largest seller was Millennium Management, cutting an estimated $1.92M.
- 85 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2025, up from 83 in Q1 2025.
- Funds reported $111M of Eledon Pharmaceuticals stock for Q2 2025, down 15% quarter-over-quarter.
- 28 funds opened new Eledon Pharmaceuticals positions in Q2 2025 and 26 closed out, a net change of +2 holders.
- The largest Eledon Pharmaceuticals buyer in Q2 2025 was BlackRock, an estimated $7.81M added.
- The largest Eledon Pharmaceuticals seller in Q2 2025 was Millennium Management, an estimated $1.92M sold.
Based on aggregated 13F filings for Q2 2025.